Terms: = Brain cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Treatment
906 results:
1. Tucatinib Combination treatment After Trastuzumab-Deruxtecan in Patients With erbb2-Positive Metastatic Breast cancer.
Frenel JS; Zeghondy J; Guérin-Charbonnel C; Mailliez A; Volant E; Poumeaud F; Patsouris A; Arnedos M; Bailleux C; Cabal J; Galland L; de Nonneville A; Guiu S; Dalenc F; Pistilli B; Bachelot T; Pierga JY; Le Du F; Bocquet F; Larrouquere L; Loirat D
JAMA Netw Open; 2024 Apr; 7(4):e244435. PubMed ID: 38568692
[TBL] [Abstract] [Full Text] [Related]
2. Prediction of cognitive decline in older breast cancer survivors: the Thinking and Living with cancer study.
McDeed AP; Van Dyk K; Zhou X; Zhai W; Ahles TA; Bethea TN; Carroll JE; Cohen HJ; Nakamura ZM; Rentscher KE; Saykin AJ; Small BJ; Root JC; Jim H; Patel SK; Mcdonald BC; Mandelblatt JS; Ahn J
JNCI Cancer Spectr; 2024 Feb; 8(2):. PubMed ID: 38556480
[TBL] [Abstract] [Full Text] [Related]
3. Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review.
Wallace G; Kundalia R; Vallebuona E; Cao B; Kim Y; Forsyth P; Soyano A; Smalley I; Pina Y
Breast Cancer Res; 2024 Mar; 26(1):55. PubMed ID: 38553702
[TBL] [Abstract] [Full Text] [Related]
4. Human Epidermal Growth Factor Receptor 2-Low Breast cancer brain Metastases: An Opportunity for Targeted Systemic Therapies in a High-Need Patient Population.
Chehade R; Nofech-Mozes S; Plotkin A; Fan KY; Das S; Sahgal A; Moravan V; Jerzak KJ
JCO Precis Oncol; 2024 Mar; 8():e2300487. PubMed ID: 38547418
[TBL] [Abstract] [Full Text] [Related]
5. Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in her2-Positive Breast cancer with brain Metastases.
Wang C; Xiang J; Zhang Q; Li J; Liu Y; Liu J
Drug Des Devel Ther; 2024; 18():909-917. PubMed ID: 38545432
[TBL] [Abstract] [Full Text] [Related]
6. Protecting the brain: Novel Strategies for Preventing Breast cancer brain Metastases through Selective Estrogen Receptor β Agonists and In Vitro Blood-brain Barrier Models.
Kirchner J; Völker E; Shityakov S; Saji S; Förster CY
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542355
[TBL] [Abstract] [Full Text] [Related]
7. Survival Analysis of Male Patients with brain Metastases at Initial Breast cancer Diagnosis over the Last Decade.
Avila J; Leone J; Vallejo CT; Leone JP
Med Sci (Basel); 2024 Mar; 12(1):. PubMed ID: 38535156
[TBL] [Abstract] [Full Text] [Related]
8. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
Strickland MR; Lander EM; Gibson MK; Ilson DH; Ajani JA; Klempner SJ
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38503041
[TBL] [Abstract] [Full Text] [Related]
9. DEGRO guideline for personalized radiotherapy of brain metastases and leptomeningeal carcinomatosis in patients with breast cancer.
Borm KJ; Behzadi ST; Hörner-Rieber J; Krug D; Baumann R; Corradini S; Duma MN; Dunst J; Fastner G; Feyer P; Fietkau R; Haase W; Harms W; Hehr T; Matuschek C; Piroth MD; Schmeel LC; Souchon R; Strnad V; Budach W; Combs SE;
Strahlenther Onkol; 2024 Apr; 200(4):259-275. PubMed ID: 38488902
[TBL] [Abstract] [Full Text] [Related]
10. Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population.
Lu Q; Wang N; Jiang K; Zhou H; Zhang P; Zhang J; Wang S; Sun P; Xu F
ESMO Open; 2024 Mar; 9(3):102389. PubMed ID: 38460250
[TBL] [Abstract] [Full Text] [Related]
11. Detection of her2 expression using
Zhao L; Xing Y; Liu C; Ma S; Huang W; Cheng Z; Zhao J
Breast Cancer Res; 2024 Mar; 26(1):40. PubMed ID: 38459598
[TBL] [Abstract] [Full Text] [Related]
12. Impact of the Breast cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study.
Sanft TB; Wong J; O'Neal B; Siuliukina N; Jankowitz RC; Pegram MD; Fox JR; Zhang Y; Treuner K; O'Shaughnessy JA
J Natl Compr Canc Netw; 2024 Mar; 22(2):99-107. PubMed ID: 38437792
[TBL] [Abstract] [Full Text] [Related]
13. Synchronous double primary small cell lung cancer and invasive ductal breast carcinoma: a case report.
Gan J; Liu M; Liu F; Wen J; Fu W; Jia J
BMC Pulm Med; 2024 Feb; 24(1):93. PubMed ID: 38388422
[TBL] [Abstract] [Full Text] [Related]
14. Leptomeningeal carcinomatosis and brain metastases in gastroesophageal carcinoma: a real-world analysis of clinical and pathologic characteristics and outcomes.
Baccili Cury Megid T; Baskurt Z; Ma LX; Barron CC; Farooq A; Saltiel MP; Wang X; Bach Y; Ayoama H; Jang RW; Chen E; Veit-Haibach P; Wang B; Kalimuthu S; Cotton J; Wong R; Mesci A; Elimova E
J Neurooncol; 2024 Mar; 167(1):111-122. PubMed ID: 38372902
[TBL] [Abstract] [Full Text] [Related]
15. Local hero: A phase II study of local therapy only (stereotactic radiosurgery and / or surgery) for treatment of up to five brain metastases from her2+ breast cancer. (TROG study 16.02).
Phillips C; Pinkham MB; Moore A; Sia J; Jeffree RL; Khasraw M; Kam A; Bressel M; Haworth A
Breast; 2024 Apr; 74():103675. PubMed ID: 38340685
[TBL] [Abstract] [Full Text] [Related]
16. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
17. Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel antibody-drug conjugates.
Natangelo S; Trapani D; Koukoutzeli C; Boscolo Bielo L; Marvaso G; Jereczek-Fossa BA; Curigliano G
Crit Rev Oncol Hematol; 2024 Mar; 195():104270. PubMed ID: 38272150
[TBL] [Abstract] [Full Text] [Related]
18. Why does her2-positive breast cancer metastasize to the brain and what can we do about it?
Xu D; Hu Z; Wang K; Hu S; Zhou Y; Zhang S; Chen Y; Pan T
Crit Rev Oncol Hematol; 2024 Mar; 195():104269. PubMed ID: 38272149
[TBL] [Abstract] [Full Text] [Related]
19. Impact of tissue-agnostic approvals on management of primary brain tumors.
Ahluwalia MS; Khosla AA; Ozair A; Gouda MA; Subbiah V
Trends Cancer; 2024 Mar; 10(3):256-274. PubMed ID: 38245379
[TBL] [Abstract] [Full Text] [Related]
20. PARP Inhibitors in Breast cancer: a Short Communication.
Daly GR; AlRawashdeh MM; McGrath J; Dowling GP; Cox L; Naidoo S; Vareslija D; Hill ADK; Young L
Curr Oncol Rep; 2024 Feb; 26(2):103-113. PubMed ID: 38236558
[TBL] [Abstract] [Full Text] [Related]
[Next]
